Profibrinolytic effect of enzamin, an extract of metabolic products from bacillus subtilis ak and lactobacillus

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 2, 2011, Pages 195-200

  Tamura, Yukinori ^a   Okada, Kiyotaka ^a   Kawao, Naoyuki ^a   Yano, Masato ^a   Ueshima, Shigeru ^b   Nagai, Nobuo ^c   Matsuo, Osamu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Bacillus subtilis AK; Endothelial cell; Fibrinolysis; Lactobacillus; Tissue type plasminogen activator

Indexed keywords

ENZAMIN; FIBRIN; FIBRINOLYTIC AGENT; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACILLUS SUBTILIS; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BINDING; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBRINOLYSIS; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ZYMOGRAPHY;

ANIMALS; BACILLUS SUBTILIS; BLOOD COAGULATION TESTS; CELL LINE; COMPLEX MIXTURES; DRUG EVALUATION, PRECLINICAL; FIBRINOLYSIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; LACTOBACILLUS; MICE; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80052464606     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0552-2     Document Type: Article

References (22)

1. Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78(12):3114-3124
2. Collen D, Lijnen HR (1995) Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 74(1): 167-171
3. Marin F, Roldan V, Lip GY (2003) Fibrinolytic function and atrial fibrillation. Thromb Res 109(5-6):233-240. doi:S0049384803002597 (Pubitemid 36724815)
4. Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA (2010) Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 55(19):2107-2115. doi:S0735-1097(10)00867-3
5. Peng Y, Yang X, Zhang Y (2005) Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. Appl Microbiol Biotechnol 69(2):126-132. doi:10.1007/s00253-005-0159-7 (Pubitemid 41795085)
6. Enzamin Research Institute (2007) Method for producing health nutritive food. Issued by Japan Patent Office, P3902015 (in Japanese)
7. The features of Enzamin. http://www.enzamin.com/product04a.html (in Japanese). Accessed 7 Oct 2010
8. Effect of Enzamin treatment in spontaneously hypertensive (SHR) rats. http://www.enzamin.com/enm09.html (in Japanese). Accessed 7 Oct 2010
9. Effect of Enzamin treatment in experimental diabetic rats. http://www.enzamin.com/enm07.html (in Japanese). Accessed 7 Oct 2010
10. Okada K, Ueshima S, Takaishi T, Yuasa H, Fukao H, Matsuo O (1996) Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase. Am J Hematol 53(3):151-157. doi: 10.1002/(SICI)1096-8652(199611)53:3<151:AID- AJH1>3.0. CO;2-Y (Pubitemid 26377732)
11. Matsuo O, Sakai T, Bando H, Okada K, Nakajima S, Takagi O, Izaki S (1986) Plasminogen activator in bronchoalveolar fluid. Haemostasis 16(1):43-50
12. Ohkura N, Oishi K, Fukushima N, Kasamatsu M, Atsumi GI, Ishida N, Horie S, Matsuda J (2006) Circadian clock molecules CLOCK and CRYs modulate fibrinolytic activity by regulating the PAI-1 gene expression. J Thromb Haemost 4(11):2478-2485. doi:10.1111/j.1538-7836.2006.02210.x (Pubitemid 44575444)
13. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A (1990) Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 63(1):82-86 (Pubitemid 20057319)
14. kurk T, Hauner H (2004) Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 28(11):1357-1364. doi:10.1038/sj.ijo.0802778 (Pubitemid 39481839)
15. Jansson JH, Johansson B, Boman K, Nilsson TK (1991) Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 229(4):309-316
16. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D (2000) Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101(3):264-269 (Pubitemid 30054153)
17. Lisman T, de Groot PG, Meijers JC, Rosendaal FR (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105(3):1102-1105. doi:10.1182/blood-2004- 08-3253 (Pubitemid 40170881)
18. Okayama T, Nakano M, Odake S, Hagiwara M, Morikawa T, Ueshima S, Okada K, Fukao H, Matsuo O (1994) Synthetic dipeptide, N-stearoyl-D-Ser-L-Pro-OEt, induces release of tissuetype plasminogen activator in cultured cells and in experimental animals. Chem Pharm Bull (Tokyo) 42(9):1854-1858 (Pubitemid 24315497)
19. Wall U, Jern S, Tengborn L, Jern C (1998) Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood 91(2):529-537 (Pubitemid 28053375)
20. Ueshima S, Matsuno H, Hayashi M, Horibuchi K, Okada K, Fukao H, Uematsu T, Matsuo O (2002) Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo. Thromb Haemost 87(6):1069-1074 (Pubitemid 34624892)
21. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24):1581-1587. doi: 10.1056/NEJM199512143332401
22. Yepes M, Roussel BD, Ali C, Vivien D (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 32(1):48-55. doi:10.1016/j.tins. 2008.09.006